Pestalozzi and Ropes & Gray advised Johnson & Johnson on a USD 500 million R&D co-funding agreement with Royalty Pharma to advance the development of JNJ-4804, an investigational co-antibody therapy targeting autoimmune diseases.
Vischer advised FimmCyte, a Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, in connection with its research collaboration and option-to-license agreement with Gedeon Richter, a pharmaceutical company specialised in women’s health, with headquarters
